Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ1366 FDC vs Co-administration in Healthy Subjects
NCT02952547Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWJ1366 in gastritis and Peptic ulcer disease (PUD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Started Oct 2016; status: completed.
02
Drugs
DWJ1366
03
Conditions
gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02952547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952547.